Article: Navigating Health Equity in 2024: The Evolution of Accountability, Part 2
In Part 2, Maureen Hennessey, SVP, Director of Value Transformation, PRECISIONvalue with Elizabeth Oyekan, VP Pharmacy and Imaging Services, Stanford Health Care and Valerie Nguyen, dive deeper into Navigating Health Equity in 2024, focusing on the significance of accreditations in addressing health disparities and promoting health equity, highlighting programs for achieving accreditation and advocating for the integration of social determinants of health (SDOH) and health equity practices within pharmacy and health care.
Article: Doubling Down on Deep Customer Insights to Inform Value Demonstration
An expert view from Ross Maclean, Head of Medical Affairs and Jon Bambalas, SVP, Business Development, Precision Value & Health, on how insights from patient-level health insurance benefits data can serve the pharmaceutical industry – namely, how coverage insights can inform the generation of evidence to demonstrate to payers and providers the value of a specific treatment.
Register for a free trial subscription and read the article HERE!
Article: Navigating Health Equity in 2024: The Evolution of Accountability, Part 1
2024 will be the first full year in which health systems will be held accountable by The Joint Commission (TJC) for performance on their National Patient Safety Goal to improve health care equity. Marueen Hennessey, SVP, Director of Value Transformation, PRECISIONvalue with Elizabeth Oyekan, VP Pharmacy and Imaging Services, Stanford Health Care and Valerie Nguyen, Healthcare Administration Graduate Intern at Stanford Health Care share their unique perspectives in this AJMC article.
Access90: Inflation Reduction Act Insight Series – Payer Controls: Two Key Questions Answered
Patients already look beyond their prescription benefits for ways to pay. As cost-sharing rises and payer formulary controls and exclusions expand, patient demand for new solutions will grow. PRECISIONvalue Chief Medical Officer Dominic Galante discusses the future of access management in this Access90 video.
On Demand: Quantifying Health Equity Impact of Innovative Healthcare Interventions
The COVID-19 pandemic laid bare disparities in access to quality healthcare and resources that have led to poor outcomes among racial and ethnic minorities, socioeconomically vulnerable individuals, and populations in rural areas. With a renewed and keener scrutiny of health equity issues, the distributional consequences of a new intervention across subgroups should come to the forefront of discussions about value in health.
Join Precision HEOR for a webinar about studying the health equity impacts of new interventions. We will outline the conceptual basis of how health interventions can affect health equity and consider distributional cost-effectiveness analysis with decision-analytic models as a practical approach to assess this quantitatively. We will discuss the evidence needs and typical gaps for new interventions and how to optimize the use of existing data. The discussion will conclude with a live Q&A.
Webinar: Implications of the IRA for Biotech Companies
This webinar will focus on the implications of the Inflation Reduction Act (IRA) on value proposition development and the evidence needed for drugs launching in 2027-2028 that plan to seek reimbursement from Medicare. Join PRECISIONvalue’s Andrew Cournoyer and Precision Value & Health’s Ross Maclean for this value packed webinar.
Access90: Inflation Reduction Act Insight Series – Rebates and WAC: Two Key Questions Answered
The Inflation Reduction Act will definitely impact established wholesale acquisition costs and rebates. Now that the Medicare bid season is upon us, how can manufacturers prepare? PRECISIONvalue expert Andrew Cournoyer, SVP of the Access Experience Team, explains in this must-see video.
PRECISIONadvisors New Office Opening in London
The PRECISIONadvisors team is looking forward to welcoming clients and Precision colleagues to their new office opening this week. The client networking event includes a panel discussion on the evolving marketing access environment in the UK featuring Andrew Walker, David Watson and Neil Grubert. Reach out to Richard Macaulay to attend!
Access90: Inflation Reduction Act Insight Series – Rebates and WAC: A Key Question Answered
When you squeeze a balloon, the air goes somewhere. Same with the cost of drugs. PRECISIONvalue expert Andrew Cournoyer, SVP of the Access Experience Team, explains the anticipated fallout from the Inflation Reduction Act in this 90-second video.
Access90: Inflation Reduction Act Insight Series – Biosimilars: A Key Question Answered (Part 2)
Biosimilars deliver dramatic reductions in drug costs—and the Inflation Reduction Act is supposed to encourage their uptake. But lower prices mean lower reimbursement, disincentivizing providers. PRECISIONvalue expert Amy Martin explains how in this 2-minute video.
